Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Deutsche Bank downgrades Moonpig to 'hold'

(Sharecast News) - Deutsche Bank downgraded Moonpig on Friday to 'hold' from 'buy' and cut the price target to 235p from 290p as it pointed to "double digit disappointment". "Rightly or wrongly, the focus in Moonpig's equity story has been its ability to deliver double digit topline growth," the bank said.

"Wrongly perhaps, as such a sharp focus does somewhat overlook the strength of margins and cash generation, but focus was very much directed here with October's CMD."

DB said that a confident KPI formula was set out and the core Moonpig brand was set to be the proof point this year.

It noted that FY25 earnings beat expectations by around 7% with a 27.6% EBITDA margin, exceeding the 25-27% target, but Moonpig revenue was up 7.5% in H2.

"Certainly not a bad performance relative to the sector, but it has invited questions as to whether the mid-term equity story can be hung off double digit topline growth to drive mid teens earnings per share growth," it said.

At 1440 BST, the shares were down 7.6% at 223.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.